Neuroprotective effects of fingolimod in mouse models of Parkinson’s disease

Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation

(2016) Qiang Liu et al.   NATURE NEUROSCIENCE

Non-invasive tracking of CD4+ T cells with a paramagnetic and fluorescent nanoparticle in brain ischemia

(2015) Wei-Na Jin et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

FTY720 attenuates excitotoxicity and neuroinflammation

(2015) Raffaela Cipriani et al.   Journal of Neuroinflammation

A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity

(2015) Qiang Liu et al.   NEUROPHARMACOLOGY

Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson’s disease and in MPP+-treated MN9D cells in vitro

(2015) M. Sivasubramanian et al.   NEUROSCIENCE

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

(2014) Emanuela Colombo et al.   ANNALS OF NEUROLOGY

Sphingosine Kinase 1 and Sphingosine-1-Phosphate in Oxidative Stress Evoked by 1-Methyl-4-Phenylpyridinium (MPP+) in Human Dopaminergic Neuronal Cells

(2014) Joanna Pyszko et al.   MOLECULAR NEUROBIOLOGY

Disturbed mitochondrial dynamics and neurodegenerative disorders

(2014) Florence Burté et al.   Nature Reviews Neurology

The ongoing pursuit of neuroprotective therapies in Parkinson disease

(2014) Dilan Athauda et al.   Nature Reviews Neurology

Ischemic neurons recruit natural killer cells that accelerate brain infarction

(2014) Y. Gan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic prospects for Parkinson disease

(2013) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

A Novel Nicotinic Mechanism Underlies  -Amyloid-Induced Neuronal Hyperexcitation

(2013) Q. Liu et al.   JOURNAL OF NEUROSCIENCE

Genetic deficiency of β2-containing nicotinic receptors attenuates brain injury in ischemic stroke

(2013) Q. Liu et al.   NEUROSCIENCE

A Guide to Neurotoxic Animal Models of Parkinson's Disease

(2013) K. Tieu   Cold Spring Harbor Perspectives in Medicine

Animal models of Parkinson’s disease

(2012) Fabio Blandini et al.   FEBS Journal

Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway

(2012) Li Gong et al.   JOURNAL OF NEUROCHEMISTRY

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome

(2012) R. Deogracias et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

(2011) Susan Duty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neurotoxin-based models of Parkinson's disease

(2011) J. Bové et al.   NEUROSCIENCE

Levodopa: the story so far

(2010) Alison Abbott   NATURE

Molecular and clinical prodrome of Parkinson disease: implications for treatment

(2010) Anthony H. V. Schapira et al.   Nature Reviews Neurology

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel Nicotinic Acetylcholine Receptor Subtype in Basal Forebrain Cholinergic Neurons with High Sensitivity to Amyloid Peptides

(2009) Q. Liu et al.   JOURNAL OF NEUROSCIENCE

Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats

(2009) Yu Hasegawa et al.   STROKE

Principles of bioactive lipid signalling: lessons from sphingolipids

(2008) Yusuf A. Hannun et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis

(2007) Kumlesh K. Dev et al.   PHARMACOLOGY & THERAPEUTICS